SCHEMBL1590771

SCHEMBL1590771

O=S(=O)(Nc1ccccc1)c1cnc2n1CCS2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.51
RAB9A P51151 6/20 0.51
MAPT P10636 2/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
POLB P06746 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2C19 P33261 1/20 0.43
ALDH1A1 P00352 8/20 0.42
NPC1 O15118 4/20 0.42
HTT P42858 3/20 0.42
KDM4E B2RXH2 1/20 0.42
LMNA P02545 1/20 0.42
HPGD P15428 1/20 0.42
STAT3 P40763 1/20 0.42
TAAR1 Q96RJ0 1/20 0.41
IL1RN P18510 1/20 0.40
KEAP1 Q14145 1/20 0.40
ERAP1 Q9NZ08 1/20 0.40
HSD17B10 Q99714 1/20 0.40
TNKS2 Q9H2K2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2252061 0.66 IL1RN (0.39) SMN1; SMN2MAPTPOLBALDH1A1HTT
SCHEMBL1202637 0.63 TNF (0.59) SMN1; SMN2MAPTALDH1A1HTTLMNA
SCHEMBL15219418 0.63 EGFR (0.59) ALDH1A1LMNAIL1RNKEAP1ERAP1
SCHEMBL12651955 0.62 ALDH1A1 (0.47) SMN1; SMN2RAB9AMAPTL3MBTL1CYP1A2
SCHEMBL6431253 0.61 KEAP1 (0.57) POLBALDH1A1KDM4EIL1RNKEAP1
SCHEMBL4031760 0.61 ALDH1A1 (0.44) SMN1; SMN2RAB9AMAPTL3MBTL1CYP1A2
SCHEMBL18716374 0.60 ALDH1A1 (0.54) SMN1; SMN2RAB9AMAPTL3MBTL1CYP1A2
SCHEMBL12797775 0.60 ALDH1A1 (0.54) SMN1; SMN2RAB9AMAPTL3MBTL1CYP1A2
SCHEMBL30916886 0.60 FKBP1A (0.47) SMN1; SMN2MAPTPOLBALDH1A1HTT
SCHEMBL25031372 0.60 KEAP1 (1.00) MAPTPOLBALDH1A1HPGDIL1RN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2324035-A1 SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS Laboratorios Del. Dr. Esteve, S.A. (ES) 2011-05-25 EP disclosed
EP-2324035-A1 SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS Laboratorios Del. Dr. Esteve, S.A. (ES) 2011-05-25 EP disclosed
US-20110092540-A1 SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2011-04-21 US disclosed
US-20110092540-A1 SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2011-04-21 US disclosed
WO-2009135927-A1 SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-11-12 WO disclosed
WO-2009135927-A1 SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS LABORATORIOS DEL DR. ESTEVE, S.A. (ES) 2009-11-12 WO disclosed
EP-2116546-A1 Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands Laboratorios Del. Dr. Esteve, S.A. (ES) 2009-11-11 EP disclosed
EP-2116547-A1 Substituted N-imidazo(2, 1-b) thiazole-5-sulfonamide derivatives as 5-TH6 ligands Laboratorios Del. Dr. Esteve, S.A. (ES) 2009-11-11 EP disclosed
EP-2116546-A1 Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands Laboratorios Del. Dr. Esteve, S.A. (ES) 2009-11-11 EP disclosed
EP-2116546-A1 Substituted N-phenyl-2,3-dihydroimidazo[2,1-b]thiazole-5-sulfonamide derivatives as 5-HT6 ligands Laboratorios Del. Dr. Esteve, S.A. (ES) 2009-11-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092540-A1 SUBSTITUTED N-PHENYL-2,3-DIHYDROIMIDAZO[2,1-B]THIAZOLE-5-SULFONAMIDE DERIVATIVES AS 5-HT6 LIGANDS HTR6, HTR2A, HTR4 SMN1; SMN2 1501/4885RAB9A 3807/4885MAPT 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.